# Anxuyuan Biotechnology (Shenzhen) Company

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anxuyuan-biotechnology-shenzhen-company

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.axbio.cn
- Total disclosed funding: $100M
- Latest round: Series B (Jun 20, 2022)
- Investors on record: 12

## About

Based in Shenzhen, China, and established in 2016, Anxuyuan Biotechnology (Shenzhen) Company Limited operates as a medical device developer that provides sequencing and diagnostic systems, biochips, and detection reagents. It has R&D centers in the United States, China, and Europe. The company has developed a microfluidic Bio-CMOS platform capable of high-throughput sequencing and molecular diagnostics that make it possible to manufacture handheld devices for bedside diagnostics to fully automate instruments for laboratories and hospitals. As of 2022, the company completed three rounds of financing.

The company provides sequencing and diagnostic systems, as well as biochips and detection reagents. They can be applied in early cancer screening and detection, rapid pathogen detection and drug development. The company also provides customized services for chemical synthesis reagents, multiple pathogen detection kits and multiple sample nucleic acid extraction kits.

## Funding rounds

- Series B, Jun 20, 2022, $100M — 5Y Capital, YF Capital, China Merchants Capital, CBC Group, Cambridge Capital, Astra Zeneca CICC Healthcare Venture Capital Fund
- Series B, Oct 31, 2021 — 5Y Capital, MSA Capital, Kaitai Capital, Yuanhe Puhua Suzhou Management
- Series A, Jan 7, 2019 — Green Pine Capital Partners, Leaguer Group, Huarun Zhengda life Science Fund

## Investors

- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A
- Leaguer Group (https://capitalatlas.ai/funds/leaguer-group) — Series A
- Huarun Zhengda life Science Fund — Series A
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Series B
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series B
- Yuanhe Puhua Suzhou Management (https://capitalatlas.ai/funds/yuanhe-puhua-suzhou-management) — Series B
- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series B
- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series B
- CBC Group (https://capitalatlas.ai/funds/cbc-group) — Series B
- Cambridge Capital (https://capitalatlas.ai/funds/cambridge-capital) — Series B
- Astra Zeneca CICC Healthcare Venture Capital Fund — Series B